Search results
Showing 8566 to 8580 of 8909 results
Discontinued Reference number: GID-TA11089
Discontinued Reference number: GID-DT9
In development Reference number: GID-TA11801 Expected publication date: TBC
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.